WHO Guidelines for Pharmacological Management of Pandemic Influenza A (H1N1) 2009 and Other Influenza Viruses: Part I: Recommendations [open pdf - 540KB]
"The purpose of this document is to provide a basis for advice to clinicians on the use of the currently available antivirals for patients presenting with illness due to influenza virus infection, as well their use for chemoprophylaxis. This document addresses the most widely available and licensed antiviral medicines, the two neuraminidase inhibitors oseltamivir and zanamivir, and the two M2 inhibitors amantadine and rimantadine. It also includes recommendations on the use of some other potential pharmacological treatments, including other investigational neuraminidase inhibitors, other agents such as arbidol, ribavirin, intranasal interferons, immunoglobulins, and corticosteroids. While the focus of the document is on management of patients with pandemic (H1N1) 2009 virus infection, it also includes guidance on the use of antivirals for seasonal influenza A and B virus strains, and for infections due to novel influenza A virus strains."
World Health Organization. Posted here from Lessons Learned Information Sharing database (LLIS). Documents are for personal use only and copyright laws apply.
Lessons Learned Information Sharing (LLIS)